National News

Price Concessions – May 2019

NPA News - 22 May 2019 - 4:23pm
Drug (pack size) Price concession Amiloride tablets 5mg  (28) £9.49 Betahistine  tablets 8mg (84) £2.61 Candesartan tablets 8mg (28) £2.50 Candesartan tablets  32mg (28) £2.49 Carvedilol tablets 12.5mg (28) £2.20 Carvedilol tablets 3.125mg (28) £1.16 Carvedilol tablets 25mg (28) £2.80 Celecoxib capsules 100mg (60) £3.29 Celecoxib capsules 200mg (30) £11.49 Celecoxib  capsules 100mg (30) £3.29 Co-careldopa tablets 25mg/100mg (100) £9.76 Ibandronic Acid tablets 50mg (28) £55.00 Ibandronic acid tablets 150mg (1) £11.00 Irbesartan tablets 150mg (28) £3.20 Irbesartan  tablets 300mg(28) £4.00 Losartan tablets 100mg (28) £3.20 Metoprolol  tablets 100mg (28) £3.30 Metronidazole 200mg tablets (21) £2.31 Naproxen gastro-resistant tablets 250mg (56) £10.00 Naproxen tablets 250mg (28) £3.76 Naproxen  gastro-resistant tablets 500mg (56) £19.25 Nortriptyline  tablets 10mg (100) £5.74 Quetiapine 200mg tablets (60) £12.10 Quetiapine 300mg tablets (60) £7.21 Riluzole tablets 50mg (56) £69.95 Sevelamer tablets 800mg (180) £127.97 Telmisartan  tablets 20mg (28) £3.22 Telmisartan tablets 80mg  (28) £6.60    …
Categories: National News

May 2019 Price Concessions – 1st update

PSNC News - 22 May 2019 - 3:30pm

Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions:

Drug Pack size Price Concession Amiloride 5mg tablets 28 £9.49 Betahistine 8mg tablets 84 £2.61 Candesartan 8mg tablets 28 £2.50 Candesartan 32mg tablets 28 £2.49 Carvedilol 3.125mg tablets 28 £1.16 Carvedilol 12.5mg tablets 28 £2.20 Carvedilol 25mg tablets 28 £2.80 Celecoxib 100mg capsules 60 £3.29 Celecoxib 200mg capsules 60 £11.49 Co-careldopa 25mg/100mg tablets 100 £9.76 Ibandronic acid 50mg tablets 28 £55.00 Ibandronic acid 150mg tablets 1 £11.00 Irbesartan 150mg tablets 28 £3.20 Irbesartan 300mg tablets 28 £4.00 Losartan 100mg tablets 28 £3.20 Metoprolol 100mg tablets 28 £3.30 Metronidazole 200mg tablets 21 £2.31 Naproxen 250mg tablets 28 £3.76 Naproxen 250mg gastro-resistant tablets 56 £10.00 Naproxen 500mg gastro-resistant tablets 56 £19.25 Nortriptyline 10mg tablets 100 £5.74 Quetiapine 200mg tablets 60 £12.10 Quetiapine 300mg tablets 60 £7.21 Riluzole 50mg tablets 56 £69.95 Sevelamer 800mg tablets 180 £127.97 Telmisartan 20mg tablets 28 £3.22 Telmisartan 80mg tablets 28 £6.60

No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated May 2019 Drug Tariff price. Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.

Categories: National News

Diamorphine 5mg injections, Microgynon 30 and Ovranette tablets – Supply update

PSNC News - 22 May 2019 - 2:59pm

Supply Update

Diamorphine 5mg injections

Accord and Wockhardt have notified the Department of Health and Social Care (DHSC) and NHS England (NHSE) that they are experiencing issues with the manufacture and availability of Diamorphine 5mg injections. There is an anticipated out of stock period between 27th May 2019 and w/c 5th August 2019. It is expected that there will be sufficient supplies of Diamorphine 10mg injections to support the forecasted use of the 5mg via usual wholesalers.

Please see the communication from DHSC for further information.

Microgynon 30 tablets

Bayer has notified DHSC that Microgynon 30 tablets will be out of stock from late May until w/c 8th July (wholesalers may have residual stock until early June), this is due to capacity constraints at their manufacturing site in Germany. Please see the communication from Bayer and DHSC for further information.

Ovranette tablets 

Pfizer have notified DHSC they will be out of stock of Ovranette tablets from early June until August 2019 due to capacity constraints.

As both Microgynon 30 and Ovranette contain ethinylestradiol 30microgram/levonorgestrel 150microgram there are several alternative suppliers, DHSC has been advised there are sufficient supplies available from certain suppliers to maintain demand throughout the duration of this supply issue. Further details can be found in the DHSC communication.

 

Categories: National News

MHRA Drug Safety Update – May 2019

NPA News - 22 May 2019 - 2:07pm
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a new Drug Safety Update on the following subjects: Lemtrada (alemtuzumab) has new restricted indications for its use and strengthened monitoring requirements while an urgent safety review evaluates reports of immune-mediated adverse reactions and serious cardiovascular events Tofacitinib (Xeljanz▼), used in rheumatoid arthritis, should not be prescribed at a dose of 10mg twice daily in patients at high risk of pulmonary embolism while a safety review on the medicine continues Administration of magnesium sulfate in pregnant women for a period of longer than 5-7 days has been associated with potential risks of hypocalcaemia, hypermagnesemia and skeletal adverse effects, neonates and monitoring should be considered for prolonged or repeated use The MHRA is urging healthcare professionals, including pharmacists, to continue reporting suspected adverse reactions to the Yellow Card Scheme following a decline in reports received during 2018 of suspected adverse drug reactions (ADRs) to the Yellow Card Scheme – every yellow card contributes to improving patient safety, do not wait for someone else to report it   For further information on this or any other query, please contact the NPA Pharmacy Services team on 01727 891 800 or email pharmacyservices@npa.co.uk.…
Categories: National News

MHRA Drug Safety Update – May 2019

NPA News - 22 May 2019 - 12:01pm
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a new Drug Safety Update on the following subjects: Lemtrada (alemtuzumab) has new restricted indications for its use and strengthened monitoring requirements while an urgent safety review evaluates reports of immune-mediated adverse reactions and serious cardiovascular events Tofacitinib (Xeljanz▼), used in rheumatoid arthritis, should not be prescribed at a dose of 10mg twice daily in patients at high risk of pulmonary embolism while a safety review on the medicine continues Administration of magnesium sulfate in pregnant women for a period of longer than 5-7 days has been associated with potential risks of hypocalcaemia, hypermagnesemia and skeletal adverse effects, neonates and monitoring should be considered for prolonged or repeated use The MHRA is urging healthcare professionals, including pharmacists, to continue reporting suspected adverse reactions to the Yellow Card Scheme following a decline in reports received during 2018 of suspected adverse drug reactions (ADRs) to the Yellow Card Scheme – every yellow card contributes to improving patient safety, do not wait for someone else to report it   For further information on this or any other query, please contact the NPA Pharmacy Services team on 01727 891 800 or email pharmacyservices@npa.co.uk.…
Categories: National News

Minor Ailments Scheme – NPA SOP launched

NPA News - 22 May 2019 - 10:22am
The Pharmacy Services team has produced a standard operating procedure (SOP) for NPA members providing the Minor Ailments Service (MAS) in Northern Ireland. The NPA welcomes The Health and Social Care Board (HSCB) announcement that the Community Pharmacy MAS Minor Ailments Service has been extended to include four additional treatment areas which include Acne Vulgaris, Haemorrhoids, Scabies and Verrucae.  In addition, cold sores can no longer be treated under the MAS. For further information on this or any other query, please contact the NPA Pharmacy Services team on 01727 891 800 or email pharmacyservices@npa.co.uk.  Produced by the NPA Pharmacy Services team May 2019…
Categories: National News

Supporting the development of primary care networks: NHS England webinars

PSNC News - 22 May 2019 - 8:30am

In order to support the ongoing development of Primary Care Networks (PCNs), NHS England will be hosting two webinars on the role of pharmacy within PCNs as part of a webinar series. The webinars are aimed at those working within primary care and the wider NHS and will include examples of work already in progress across the country, and provide viewers with the opportunity to ask questions and learn more about the next steps in the development of PCNs.

The two webinars on working with pharmacy will be held on:

There is no need to register in advance; simply click on the above links at the start time.

Other webinar topics included in the series will look at how to best use technology to develop services, engaging with people and communities, using the wider workforce and estates.

For further information and resources on PCNs, visit psnc.org.uk/pcn

Categories: National News

Feedback on our Future of Pharmacy Animation

PSNC News - 21 May 2019 - 12:45pm
Please share your thoughts with us

Last month PSNC launched a video animation explaining how community pharmacy will fit into the NHS of the future. The animation should help contractors to understand what will be expected of pharmacies in the future and how they can start to prepare for that.

We would like to hear feedback from those working in community pharmacy to make sure that the animation is useful and to find out whether this is a communications style that we should use again going forwards.

If you haven’t seen our animation already please watch it here:

Watch the animation

Please share your thoughts with us by filling in the feedback survey at the link below.

Give your feedback on the animation

If you would like to find out more about the animation, please visit: psnc.org.uk/futureofpharmacy

 

Categories: National News

MHRA Drug Safety Update May 2019

PSNC News - 20 May 2019 - 11:57am

Date issued: 17th May 2019

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 10 May 2019:1) has been published and includes articles on:

  • Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements.
  • Tofacitinib (Xeljanz ▼) : restriction of 10mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing.
  • Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy.
  • Yellow Card: Please help to reverse the decline in reporting of suspected adverse drug reactions.
  • Letters and drug alerts sent to healthcare professionals in April 2019
  • Medical Device Alerts issued in April 2019

To see the latest MHRA Drug Safety Update in full, visit the GOV.uk website.

 

Categories: National News

CPAF screening process to start in June

PSNC News - 17 May 2019 - 3:11pm

The 2019/20 Community Pharmacy Assurance Framework (CPAF) screening questionnaire will soon be available for completion from Monday 3rd June 2019 until Sunday 30th June 2019.

The process asks all NHS community pharmacy contractors to complete a short screening questionnaire consisting of 10 active questions which should be answered; NHS England will then select a small number of pharmacies for a monitoring visit and/or to complete the full CPAF questionnaire.

Last year’s CPAF screening process was positive with 98.2% of contractors responding to the CPAF screening questionnaire.

PSNC has worked with NHS England to reflect upon and review contractor feedback from last year’s screening survey. Contractor feedback showed that pharmacies aimed to attain level 3 and exceed their terms of service. Therefore, PSNC agreed with NHS England new wording to the safeguarding question to make it possible for contractors to attain Level 3 without requiring a safeguarding issue to have occurred in their pharmacy. More information will be provided in PSNC’s updated guidance which we are currently finalising.

This year’s screening questionnaire has also been updated so that the pharmacy based audit question relates to contractors’ 2018/19 audit activity. Contractors should have undertaken at least one clinical audit on a topic of their choice; in addition to the NHS England’s nationally determined audit on the provision of advice to people with diabetes on the importance of them receiving an annual seasonal influenza vaccination. Clinical audit guidance is available on the PSNC website.

Level 2 is the minimum standard expected to demonstrate general compliance with the terms of service.

Community pharmacies are able to view the questionnaire here in advance. Please note this is in PDF format and cannot be submitted. Community pharmacies should receive information and instructions on how to complete the screening questionnaire either via email from the NHS Business Services Authority (NHSBSA) or from their own Head Office. Contractors are advised to contact NHSBSA by emailing nhsbsa.cpaf@nhs.net if they have not received details of the questionnaire by week commencing 27 May 2019, or if they have any problems or queries completing the questionnaire.

Categories: National News

Sinemet – Supply update and notice of change of appearance

PSNC News - 17 May 2019 - 9:02am
Supply Update

Merck Sharp & Dohme Limited (MSD) are still experiencing intermittent supply issues which are expected to continue until early June with the following products:

  • Sinemet 25mg/250mg 10×10 tablets.
  • Sinemet 12.5mg/50mg 9×10 tablets.
  • Sinemet CR 50mg/200mg 6×10 tablets.
  • Sinemet plus 10mg/100mg 10×10 tablets.

MSD have confirmed the following Sinemet products should now be available:

  • Sinemet Plus 25mg/100mg 10×10 tablets.
  • Sinemet Half CR 25mg/100mg 6×10 tablets.
Change of appearance

With a view to providing a more consistent supply MSD have moved manufacturing of 3 Sinemet products to another manufacturing site. This move means that the appearance of 3 Sinemet products will change from round to oval.

The 3 products that will change their appearance from early May are:

  • Sinemet 10mg/100mg tablets
  • Sinemet 25mg/250mg tablets
  • Sinemet Plus 25mg/100mg tablets

For more information and news on Sinemet visit the Parkinson’s UK website.

Please visit the MSD supply page for the latest updates here or contact MSD UK customer services on 01992 452094 (during public holidays contact MSD UK switchboard on 01992 467272).

 

Categories: National News

PCSE invitation to contractors to test market entry online portal

PSNC News - 16 May 2019 - 5:01pm

In March, PSNC announced that market-entry applications were to move online as PCSE confirmed a new approach for pharmacy applications which will see the replacement of multiple paper forms with one single online application, accessible via PCSE Online.

PSNC has been and will continue to work with PCSE on the development of the market-entry online portal and confirm that the PCSE Engagement team would like to offer contractors a preview of the online application system. There will be opportunities to share any feedback, to participate in testing, and even be one of the first to use the system before it is launched nationally. The PCSE Engagement team have kindly provided a PDF preview which illustrates how the online portal will look which is subject to change during the developmental phase.

For further information on the above session please contact the PCSE Pharmacy engagement team pcse.pharmacyengagement@nhs.net

Categories: National News

Community pharmacy diary

NPA News - 16 May 2019 - 9:34am
Dear Superintendent, In a busy pharmacy environment it is easy to forget relevant deadlines and dates that pharmacy teams may need to be aware of. In addition, it is easy to forget the finer details of endorsing prescriptions. With that in mind I am pleased to highlight a new resource, the ‘pharmacy diary’ that will allow you to keep on top of important dates and support you with completing your end of month submission. To access this resource please click here. The community pharmacy diary will help you: Keep track of key deadlines and events Remember to carry out important day-to-day and monthly tasks, for example filling out the Responsible Pharmacist log and record fridge temperatures Add reminders for your own key dates How to use the community pharmacy diary Each page represents one month of the year – from April 2019 to March 2020 The two columns on the left shows the day and day of month The third column shows the key deadline or event The last column shows ongoing daily and monthly tasks For each day of the month there is space to add in your own key dates – for example locally commissioned service claim deadline The community pharmacy diary will continue to be updated as and when new dates are published Three appendices have also been included within the diary to help ensure you receive correct payment from your end of month prescription submission: Appendix 1 – Checklist to ensure correct payment including top tips for submission Appendix 2 – Sorting your submission bundle Appendix 3 – Completing the FP34C If you have any feedback or suggestions about the resource please let me know.…
Categories: National News

Book now for our Schedule of Payments webinar

PSNC News - 15 May 2019 - 1:00pm

PSNC and the NHS Business Services Authority (NHSBSA) will be holding a Schedule of Payments webinar on Tuesday 11th June at 7.30pm.

The webinar will aim to help community pharmacy contractors to better understand their FP34 Schedule of Payments.

Webinar Details When is it?
Tuesday 11th June at 7.30pm.

Who should attend
Every community pharmacy contractor who wants to better understand their pharmacy’s monthly payments.

How do I register?
Please click here to sign up.

During the online event PSNC and NHSBSA will:

  • Explain how your pharmacy’s monthly Schedule of Payments is put together;
  • Highlight how potential discrepancies between the FP34c and FP34 can creep in;
  • Describe where to find various fees and payments in the Schedule;
  • Illustrate why your monthly payments may fluctuate; and
  • Show you how to use your Schedule to monitor performance.

During the 60-minute webinar viewers will also be given the opportunity to ask questions.

So, if you want to better understand the payments your pharmacy receives from the NHS, please join us for the ‘Understanding your Schedule of Payments’ webinar.

Book your place now

Unable to attend the webinar?
Don’t worry, you will be able to watch a recording on the PSNC website a few days after the event.

Categories: National News

Faxes from pharmacies are still being sent to incorrect recipients –update

NPA News - 15 May 2019 - 12:10pm
NHS England has received further reports from the same hotel group who are continuing to receive faxed anonymised prescriptions from pharmacies. The fax number of the hotel group, (0330 333 2812) is very similar to that of Alliance Healthcare’s prescription validation service fax number 0330 332 8126. Pharmacy teams should check that the Alliance Healthcare fax number held at the pharmacy has been recorded correctly to avoid faxes being unintentionally sent to a different recipient. NHS England has provided the following advice for pharmacists and their teams: Only use fax as a way of communication if no other method is available Confirm the fax number with the recipient prior to sending Confirm the fax has been received by the recipient after sending Any updates to the pharmacy’s contact details should be shared with relevant healthcare contacts Any breach of personal data must be reported appropriately so that the necessary investigation can be undertaken and learnings can be shared. …
Categories: National News

IMPORTANT: Making Tax Digital for VAT – are you prepared?

NPA News - 14 May 2019 - 3:20pm
*Updated 14 May 2019 to include changes to use of supplier statement* Dear Superintendent, The Pharmacy Services team has received enquiries from members regarding compliance with Making Tax Digital (MTD) requirements which come into effect from 1 April 2019. I would like to highlight the main aspects that members find confusing, as well as the support available from the NPA to allow you to make a smooth transition as applicable to your business. *Please see the updated information in the FAQs section below on use of supplier statements to record VAT totals* Making Tax Digital (MTD) From Monday 1 April 2019, all businesses with a taxable turnover above the VAT registration threshold (currently £85,000) must comply with the requirements of ‘Making Tax Digital (MTD) for VAT’ — all VAT returns will need to be submitted digitally to HM Revenue & Customs (HMRC). This means that from 1 April 2019, most businesses will no longer be able to use manual/paper based records to submit their VAT returns to the HMRC.…
Categories: National News

Unplanned customer service disruption

PSNC News - 14 May 2019 - 3:05pm

We are having some technical difficulties so may not be able to answer our phones and emails today.

Normal service will be resumed as quickly as possible.

In the meantime, please explore our website which contains a wealth of information, guidance and resources.

Apologies for any inconvenience caused.

Categories: National News

Opportunity to develop community pharmacy across Kent

PSNC News - 14 May 2019 - 10:47am

Are you an exceptional strategic thinking individual who can provide innovative solutions to support and develop community pharmacy? If so, we may have the ideal job opportunity for you.

Kent Local Pharmaceutical Committee (LPC) is looking to recruit a new Chief Executive Officer. This exciting key leadership full time role offers the perfect opportunity for an experienced pharmacist leader to build on the work of the previous CEO, as well as grasping opportunities that will present themselves arising out of the NHS 5 year plan and the evolving LPC strategy and business plan.

This opportunity to represent 334 community pharmacy contractors across Kent has become available due to the current CEO moving role.

Further information about the role, including details of how to apply, can be found here. The closing date for applications is 18th May 2019.

Categories: National News

Update: are you faxing to the intended recipient?

PSNC News - 13 May 2019 - 2:34pm

Further to a news story published earlier this year, NHS England has received further reports from the same hotel chain of faxes being received from pharmacies, which were not intended for the hotel.

The hotel chain in question (fax number 0330 333 2812), which has been receiving faxes containing anonymised prescriptions, has a very similar fax number to the one belonging to Alliance Healthcare’s prescription validation service (fax number 0330 332 8126).

It can therefore be presumed that some pharmacy teams intended to send a fax to Alliance Healthcare, but the messages were inadvertently being sent to a different recipient instead.

All pharmacy teams that may have to send faxes to Alliance Healthcare’s prescription validation service are asked to check that their record of the fax number held at the pharmacy is correct.

Pharmacy teams are also reminded of NHS England’s previous advice when using fax machines:

  • only use fax where no other communication method is available;
  • before sending a fax, confirm with the recipient that the number is correct; and
  • after sending a fax, confirm with the recipient that they have correctly received your transmission.

Any breaches of information governance security should be reported so that the incident can be investigated and learning shared where necessary.

Categories: National News

Class 2 MHRA Medicines Recall – Co-amoxiclav 125mg/31.25mg/5ml & 250mg/62.5mg/5ml powder for oral suspension (Sandoz Ltd)

PSNC News - 13 May 2019 - 12:15pm

Drug alert number: EL (19) A/12
Date issued: 13th May 2019 

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 pharmacy level medicines recall, to be actioned within 48 hours, for certain batches of co-amoxiclav 125mg/31.25mg/5ml powder for oral suspension and 250mg/62.5mg/5ml powder for oral suspension.

Sandoz Limited is recalling the batches identified below from pharmacies as a precautionary measure due to a potential packaging problem relating to poor seal adherence which could cause clumping of the powder within the bottle. A poor bottle seal could lead to degradation of the clavulanic acid within the powder and could potentially render the product ineffective.

Co-amoxiclav 125mg/31.25mg/5ml powder for oral suspension PL 04416/0514

Co-amoxiclav 250mg/62.5mg/5ml powder for oral suspension PL 04416/0515

Batch Number Expiry Date Pack Size First Distributed   HT6202   Feb 2021   100ml   Sep 2018   HT7923   Feb 2021   100ml   Jul 2018

Community pharmacy teams should stop supplying the above products/batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.

To view the alert please visit the GOV.UK website.

Company contacts for further information

For stock control enquiries please contact Sandoz Limited Customer Services on 01276 698607 or email sales.sandoz-gb@sandoz.com

For medical information enquiries please contact Sandoz Medical Information Team on 01276 698101 or email sandozgb@EU.propharmagroup.com

Categories: National News
Syndicate content
Continuing Professional Development Just visiting this site means you are probably performing CPD - record it online at www.uptodate.org.uk
Site developed by Gary Warner
Drupal theme by Kiwi Themes.